Technology | Heart Valve Technology | November 09, 2017

4C Medical's Novel Transcatheter Mitral Valve Presented at TCT 2017 Shark Tank Innovation Competition

Device employs a unique supra-annular, atrial-only fixation approach

4C Medical's Novel Transcatheter Mitral Valve Presented at TCT 2017 Shark Tank Innovation Competition

November 9, 2017 — 4C Medical Technologies Inc. announced that its medical device for mitral regurgitation (MR) was presented at the Shark Tank Innovation Competition at the Transcatheter Cardiovascular Therapeutics (TCT) meeting, held Oct. 29-Nov. 2, 2017 in Denver. The device was one of the eight innovations selected among nearly fifty submissions.

4C Medical is developing the first MR treatment that preserves the native mitral valve and left ventricle using a supra-annular, atrial-only fixation technology. The novel design eliminates issues associated with current transcatheter mitral valve replacement (TMVR) technologies – which rely on placement and fixation in the native mitral annulus and left ventricle – such as obstruction of the left ventricular outflow tract, impaired function of the left ventricle and device embolization.

Philippe Généreux, M.D., presented "A Novel Transcatheter Mitral Valve Replacement Technology (4C)," in which he explained how the design and supra-annular placement of the 4C valve may extend TMVR therapy to patients who would be ineligible for alternative TMVR procedures based on the irregular anatomy of their mitral annulus or left ventricle or presence of severe calcification. Généreux is co-director of the Structural Heart Program at the Gagnon Cardiovascular Institute of Morristown Medical Center (Morristown, N.J.) and a practicing interventional cardiologist at Hôpital du Sacré-Coeur de Montréal (Montreal, Canada).

Watch the VIDEO “TAVR For Asymptomatic Severe Aortic Stenosis,” an interview with Généreux at TCT 2017.

"One aspect that excites me most about the 4C valve is that it is the only scalable technology that will provide treatment options for a broad MR patient population," said Généreux. "Because the device is placed and anchored entirely in the left atrium, it does not rely on or interact with the dynamic and irregular anatomy of the mitral annulus and left ventricle. Additionally, the 4C valve may be delivered transapically or transseptally, which gives options to operators. No other valve in development today can offer the same advantages. 4C Medical's technology will answer a real unmet clinical need."

Watch the VIDEO: Cath Lab of the Future Cardiovascular Technologies to Watch at TCT 2017  — with Juan Granada, M.D.

For more information: www.4cmed.com

Related Content

Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
Videos | Cath Lab | September 14, 2018
A discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS.
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Overlay Init